Global Innovative Platforms Inc (GIPL) is a pre-revenue animal healthcare diagnostics company developing a non-invasive breath-based test to detect heartworm in dogs. The company has generated no revenue as of the fiscal year ended September 30, 2025, as its technology was not market-ready during FY2025 or FY2024. GIPL's approach uses a proprietary Breath Capture Device paired with a licensed VOCAM Plus gas chromatograph to identify volatile organic compounds (VOCs) in dog breath that indicate heartworm presence. The company holds an exclusive, global Patent and Know-How License Agreement with Defiant Technologies Inc., signed August 27, 2024, covering animal testing and all commercial applications in the animal market. GIPL has one full-time executive, Andrew Brown, who serves as sole director and CEO. The company's auditor has issued a going concern opinion citing recurring losses as of September 30, 2025. GIPL is incorporated in the United States and files under SEC Section 12(g) with common stock at $0.0001 par value.

Revenue model

No revenue recognized in FY2025 or FY2024. The company's disclosed commercial plan, not yet operational, anticipates a per-use fee model for breath sample analysis, with units potentially placed at animal healthcare facilities and charged on a per-use basis via Bluetooth or 5G connection.

Products and services

Breath Capture Device: a canine breath collection device adaptable to different muzzle sizes. VOCAM Plus gas chromatograph: licensed from Defiant Technologies Inc. under a Patent and Know-How License Agreement (executed August 27, 2024), used to analyze VOC breathprints from collected breath samples. The heartworm breath test is in development and not yet commercialized as of FY2025.

Customers and end markets

Target end market is veterinary and animal healthcare facilities in the U.S. and Canada. End users anticipated to be veterinarians and animal health professionals. No commercial customers as of September 30, 2025.

Value-chain role

Early-stage diagnostic device developer and licensor. GIPL develops the breath collection hardware and licenses gas chromatograph technology from Defiant Technologies Inc. Laboratory analysis is anticipated to be performed through third-party labs in New Mexico and Oklahoma during pre-commercialization. The company does not plan to build an exclusive laboratory.

Geographic exposure

Operations based in Florida (current lab) with anticipated commercial laboratory network in the U.S. and Canada. License from Defiant Technologies Inc. covers global animal market applications.

Source: SEC 10-K, filed 2026-01-13

Industry: Surgical & Medical Instruments & Apparatus Peers: NVIDIA Corp Peraso Inc NanoFlex Power Corp Mosaic Immunoengineering Inc Datavault AI Inc SPI Energy Co., Ltd. Solitron Devices Inc